Feature | Radiation Therapy | October 21, 2016 | Dave Fornell

Company has continued to produce, sell and service non-FDA cleared devices for radiation therapy

Multidata Systems International Corp, water phantom, FDA warning

October 21, 2016 — The U.S. Food and Drug Administration (FDA) issued a letter calling on radiation oncologists, medical physicists, dosimetrists and radiation therapists to stop using all medical devices manufactured and sold by Multidata Systems International Corp. The FDA said it is concerned about the risks to patients from the use of devices, which never received FDA market clearance. 

William Maisel, M.D., MPH, deputy for the Center Director for Science, Center for Devices and Radiological Health, FDA, said the agency knows of at least two Multidata medical devices that the company manufactured and distributed in the United States for which FDA never received nor reviewed 510(k) premarket notifications. These devices include: (1) accessories to radiation therapy devices including the Real Time Dosimetry (RTD) Waterphantom System; and (2) the Dual Channel Electrometer. In addition, Multidata has not registered or listed their devices with the FDA, as required by federal law.

Since 2003, Multidata has been under a Consent Decree of Permanent Injunction entered by the U.S. District Court for the Eastern District of Missouri (civil action no. 4:03cv575). Maisel said the decree prohibits Multidata from designing, manufacturing, processing, and distributing medical devices, among other restrictions. The FDA has learned, however, that Multidata manufactured and distributed medical devices in violation of the decree, including repairing and exchanging waterphantom devices for newer design models.

“The FDA is concerned that healthcare providers may be unaware of the risks associated with these devices and urges facilities to discontinue the use of any devices manufactured by Multidata,” Maisel said. He explained these need to be dispose of appropriately and replaced with accessories to radiation therapy devices and radiation treatment planning software that have been reviewed and cleared by FDA.

Analysis of the Problem

At this time, it is not known how many devices manufactured by Multidata are currently in use in hospitals and clinics throughout the United States. The FDA is not aware of adverse event reports associated with the use of Multidata's devices since Multidata has been under the decree, but because the FDA has not received or reviewed 510(k) premarket notifications, the agency is concerned about the potential risk to patients from the devices.

FDA Recommendations

In a letter to providers, Maisel urged discontinuing the use of any devices manufactured by Multidata and disposal of them appropriately. The FDA urges use of accessories to radiation therapy devices and radiation treatment planning software that have been cleared by the FDA. Registered manufacturers of these types of devices are listed under the IYE product code in the FDA’s Registration and Listing Database (www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm).

Maisel also said centers should follow quality assurance procedures to verify treatment plans by independent means, which may include manual calculations or measurements of radiation doses.

FDA Actions

Through inspections, the FDA learned that Multidata was designing, manufacturing, processing and distributing medical devices in violation of the decree. As a result, on March 3, 2016, the FDA sent a letter to Multidata ordering the firm to cease designing, manufacturing, processing, packing, repacking, labeling, installing, holding for sale and distributing any medical device. The company has now permanently ceased operations and will be dissolving.

The FDA will keep the public informed if significant new information becomes available, Maisel said. 


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
News | Digital Pathology

July 12, 2024 — Diagnosing cancer and providing the personalized therapy it often requires, is a collaborative effort ...

Time July 12, 2024
arrow
Subscribe Now